Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Afinitor Wins FDA Nod For Kidney Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

The mTor inhibitor targets Sutent or Nexavar treatment failures.
Advertisement

Related Content

Lilly Prepares for Sales Pressures in 2011 to 2014
Lilly Prepares for Sales Pressures in 2011 to 2014
Supplemental Approval For Benign Tumors May Double Afinitor's Market
RCC Market Snapshot: In A Crowded Field, What's Next?
Far From Certican: Novartis Hopes REMS Will Tip Balance For Kidney Transplant Drug
Another Go At Certican: Novartis Transplant Agent To Go To Advisory Committee
Adventures in Glutamate: The Difficult and Expensive Path of Novelty in Drug Discovery
Last Gasp Or New Life? 2009’s Novel Products Have Blockbuster Potential
Novartis Oncology Pipeline Has Lucky 13 Clinical Candidates
Wyeth’s Torisel To Launch In July Following FDA Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS069202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel